Cargando…
Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments
Tuberculosis (TB), historically the most significant cause of human morbidity and mortality, has returned as the top infectious disease worldwide, under circumstances worsened by the COVID-19 pandemic's devastating effects on public health. Although Mycobacterium tuberculosis, the causal agent,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839462/ https://www.ncbi.nlm.nih.gov/pubmed/36646193 http://dx.doi.org/10.1016/j.nano.2023.102653 |
_version_ | 1784869488789815296 |
---|---|
author | Valdemar-Aguilar, Carlos M. Manisekaran, Ravichandran Acosta-Torres, Laura S. López-Marín, Luz M. |
author_facet | Valdemar-Aguilar, Carlos M. Manisekaran, Ravichandran Acosta-Torres, Laura S. López-Marín, Luz M. |
author_sort | Valdemar-Aguilar, Carlos M. |
collection | PubMed |
description | Tuberculosis (TB), historically the most significant cause of human morbidity and mortality, has returned as the top infectious disease worldwide, under circumstances worsened by the COVID-19 pandemic's devastating effects on public health. Although Mycobacterium tuberculosis, the causal agent, has been known of for more than a century, the development of tools to control it has been largely neglected. With the advancement of nanotechnology, the possibility of engineering tools at the nanoscale creates unique opportunities to exploit any molecular type. However, little attention has been paid to one of the major attributes of the pathogen, represented by the atypical coat and its abundant lipids. In this review, an overview of the lipids encountered in M. tuberculosis and interest in exploiting them for the development of TB control tools are presented. Then, the amalgamation of nanotechnology with mycobacterial lipids from both reported and future works are discussed. |
format | Online Article Text |
id | pubmed-9839462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98394622023-01-17 Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments Valdemar-Aguilar, Carlos M. Manisekaran, Ravichandran Acosta-Torres, Laura S. López-Marín, Luz M. Nanomedicine Original Article Tuberculosis (TB), historically the most significant cause of human morbidity and mortality, has returned as the top infectious disease worldwide, under circumstances worsened by the COVID-19 pandemic's devastating effects on public health. Although Mycobacterium tuberculosis, the causal agent, has been known of for more than a century, the development of tools to control it has been largely neglected. With the advancement of nanotechnology, the possibility of engineering tools at the nanoscale creates unique opportunities to exploit any molecular type. However, little attention has been paid to one of the major attributes of the pathogen, represented by the atypical coat and its abundant lipids. In this review, an overview of the lipids encountered in M. tuberculosis and interest in exploiting them for the development of TB control tools are presented. Then, the amalgamation of nanotechnology with mycobacterial lipids from both reported and future works are discussed. Elsevier Inc. 2023-02 2023-01-14 /pmc/articles/PMC9839462/ /pubmed/36646193 http://dx.doi.org/10.1016/j.nano.2023.102653 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Valdemar-Aguilar, Carlos M. Manisekaran, Ravichandran Acosta-Torres, Laura S. López-Marín, Luz M. Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments |
title | Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments |
title_full | Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments |
title_fullStr | Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments |
title_full_unstemmed | Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments |
title_short | Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments |
title_sort | spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839462/ https://www.ncbi.nlm.nih.gov/pubmed/36646193 http://dx.doi.org/10.1016/j.nano.2023.102653 |
work_keys_str_mv | AT valdemaraguilarcarlosm spotlightonmycobacteriallipidexploitationusingnanotechnologyfordiagnosisvaccinesandtreatments AT manisekaranravichandran spotlightonmycobacteriallipidexploitationusingnanotechnologyfordiagnosisvaccinesandtreatments AT acostatorreslauras spotlightonmycobacteriallipidexploitationusingnanotechnologyfordiagnosisvaccinesandtreatments AT lopezmarinluzm spotlightonmycobacteriallipidexploitationusingnanotechnologyfordiagnosisvaccinesandtreatments |